These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25232824)

  • 1. The role of iron in prion disease and other neurodegenerative diseases.
    Singh N
    PLoS Pathog; 2014 Sep; 10(9):e1004335. PubMed ID: 25232824
    [No Abstract]   [Full Text] [Related]  

  • 2. THERPA: A small molecule database related to prion protein regulation and prion diseases progression.
    Lee SM; Lee W; Lee YS; Yoo JS; Park SJ; Kim H; Kim SY
    Prion; 2018 Mar; 12(2):138-142. PubMed ID: 29633896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease.
    Singh N; Haldar S; Tripathi AK; McElwee MK; Horback K; Beserra A
    Antioxid Redox Signal; 2014 Jul; 21(3):471-84. PubMed ID: 24512387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovering the mechanisms of neurodegeneration in prion diseases.
    DeArmond SJ
    Neurochem Res; 2004 Nov; 29(11):1979-98. PubMed ID: 15662833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POSCAbilities: The Application of the Prion Organotypic Slice Culture Assay to Neurodegenerative Disease Research.
    Pineau H; Sim V
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32698402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prion-Like Characteristics of Polyglutamine-Containing Proteins.
    Pearce MMP; Kopito RR
    Cold Spring Harb Perspect Med; 2018 Feb; 8(2):. PubMed ID: 28096245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit.
    Guest WC; Silverman JM; Pokrishevsky E; O'Neill MA; Grad LI; Cashman NR
    J Toxicol Environ Health A; 2011; 74(22-24):1433-59. PubMed ID: 22043906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated manganese levels in blood and CNS in human prion disease.
    Hesketh S; Sassoon J; Knight R; Brown DR
    Mol Cell Neurosci; 2008 Mar; 37(3):590-8. PubMed ID: 18234506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis).
    Gaggelli E; Kozlowski H; Valensin D; Valensin G
    Chem Rev; 2006 Jun; 106(6):1995-2044. PubMed ID: 16771441
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiphysics of Prionlike Diseases: Progression and Atrophy.
    Weickenmeier J; Kuhl E; Goriely A
    Phys Rev Lett; 2018 Oct; 121(15):158101. PubMed ID: 30362787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration.
    Costanzo M; Zurzolo C
    Biochem J; 2013 May; 452(1):1-17. PubMed ID: 23614720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglial cells in neurodegenerative disorders.
    Wojtera M; Sikorska B; Sobow T; Liberski PP
    Folia Neuropathol; 2005; 43(4):311-21. PubMed ID: 16416395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of metals in neurodegenerative diseases.
    Sayre LM; Perry G; Atwood CS; Smith MA
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):731-41. PubMed ID: 10875436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases.
    Walker LC
    Annu Rev Genet; 2016 Nov; 50():329-346. PubMed ID: 27893962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cytokines and chemokines in prion infections of the central nervous system.
    Burwinkel M; Riemer C; Schwarz A; Schultz J; Neidhold S; Bamme T; Baier M
    Int J Dev Neurosci; 2004 Nov; 22(7):497-505. PubMed ID: 15465279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases.
    Jucker M; Walker LC
    Nature; 2013 Sep; 501(7465):45-51. PubMed ID: 24005412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REST alleviates neurotoxic prion peptide-induced synaptic abnormalities, neurofibrillary degeneration and neuronal death partially via LRP6-mediated Wnt-β-catenin signaling.
    Song Z; Zhu T; Zhou X; Barrow P; Yang W; Cui Y; Yang L; Zhao D
    Oncotarget; 2016 Mar; 7(11):12035-52. PubMed ID: 26919115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A transmembrane form of the prion protein in neurodegenerative disease.
    Hegde RS; Mastrianni JA; Scott MR; DeFea KA; Tremblay P; Torchia M; DeArmond SJ; Prusiner SB; Lingappa VR
    Science; 1998 Feb; 279(5352):827-34. PubMed ID: 9452375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein aggregation and prionopathies.
    Renner M; Melki R
    Pathol Biol (Paris); 2014 Jun; 62(3):162-8. PubMed ID: 24698014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microglia in prion diseases.
    Aguzzi A; Zhu C
    J Clin Invest; 2017 Sep; 127(9):3230-3239. PubMed ID: 28714865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.